Use of intrathecal chemoprophylaxis in children after SCT and the risk of central nervous system relapse
2011 (English)In: Bone Marrow Transplantation, ISSN 0268-3369, E-ISSN 1476-5365, Vol. 46, no 3, 372-378 p.Article in journal (Refereed) Published
Conflicting conclusions can be drawn from the available data concerning antileukemic efficacy and risks of intrathecal (i.t.) chemoprophylaxis to children after hematopoietic SCT (HSCT). To address this, we enrolled six transplantation centers with similar treatment and patient material. Of the 397 children included, 136 patients had received post-HSCT i.t. treatment (i.t. group) and 261 had not (non-i.t. group). The two groups were, apart from the i.t. therapy given or not given, at equal risk of post-HSCT central nervous system (CNS) relapse, which was the primary endpoint studied. Isolated CNS relapses were observed in 2 (1.5%) patients from the i.t. group and 2 (1%) from the non-i.t. group. Combined relapses, including CNS, involved 4 (3%) patients from the i.t. group and 6 (2%) from the non-i.t. group. Overall survival and the occurrence of neurological side effects did not differ significantly between the groups. There was no statistically significant difference in the incidence of isolated or mixed CNS relapses between the two groups, suggesting little or no benefit from i.t. therapy post-HSCT in children.
Place, publisher, year, edition, pages
2011. Vol. 46, no 3, 372-378 p.
Hematopoietic SCT, Intrathecal therapy, CNS relapses
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-130839DOI: 10.1038/bmt.2010.121ISI: 000288164000009PubMedID: 20498650OAI: oai:DiVA.org:uu-130839DiVA: diva2:351475